Cadisegliatin is being tested as an extra treatment for people with Type 1 Diabetes who are already using insulin. This study will last for 26 weeks, which is about six months. It will compare how well cadisegliatin works, alongside insulin, to reduce dangerous low blood sugar levels (hypoglycemia) compared to using insulin alone. Participants must be 18 or older, have had Type 1 Diabetes for at least five years, and have experienced a serious low blood sugar event recently.

Participants must also currently use insulin in a specific way and have used a continuous glucose monitor (CGM) for at least three months. People cannot join if they have other forms of diabetes, uncontrolled thyroid issues, or if they have had certain health problems like an eating disorder recently. Also, participants should not have used certain diabetes medications or hybrid insulin pumps recently.

• Duration: 26 weeks of treatment.
• Eligibility: Must have Type 1 Diabetes for 5+ years, aged 18+, and meet specific health criteria.
• Restrictions: Cannot use certain medications or hybrid insulin systems.